Sirnaomics, Inc.

HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the " Company", together with its subsidiaries, the " Group" or " Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, announced that the Company has entered into a subscription agreement with Dr. Poon Hung Fai ("Dr. Poon"), the subscriber. Dr. Poon intends to subscribe for 17,527,696 subscription shares at a subscription price of approximately HK$3.36 per share, representing approximately 16.7% of the issued share capital of the Company as enlarged by the allotment and issue of the subscription shares. The gross proceeds of the subscription will be approximately HK$58.9 million. Dr. Poon's extensive experience and successful background in the biotechnology sector will help drive the Group's business development and drug R&D process, further enhancing the Group's core competitiveness. In addition, Dr. Poon's keen market insight will facilitate the Group's strategic planning and resource allocation, and help the Group achieve long-term growth and sustainable development. Dr. Patrick Lu, Founder, Chairman of the Board and CEO of Sirnaomics, said: "We are very pleased to sign the subscription agreement with Dr. Poon, which will not only provide significant financial support to Sirnaomics, but also further optimize our shareholding structure. With Dr. Poon's extensive experience and successful track record in the biopharma industry, coupled with Sirnaomics' pioneering and solid business foundation in nucleic acid drug innovation, we believe that this strong partnership will provide the Group with great opportunities to advance its lead products and broaden its business development horizon, as well as strengthen the Group's financial health." About Sirnaomics Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Company's GalAhead™ technology, is currently in Phase I development. The Company has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the establishment of the Group's manufacturing facility in China, Sirnaomics is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: . SOURCE Sirnaomics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the " Company", Stock Code: 2257, together with its subsidiaries, the " Group" or " Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the company in collaboration with Dr. Mark Nestor's team from the Center for Clinical and Cosmetic Research in Miami Florida has jointly published a major breakthrough for its novel siRNA therapeutics revealing a novel mechanism of action of a significant reduction of adipose tissue in preclinical animal models. This groundbreaking work entitled "Novel injectable polypeptide nanoparticle encapsulated siRNA targeting TGF-β1 and COX-2 for localized fat reduction I: Preclinical in vitro and animal models", published at Journal of Cosmetic Dermatology, 2024; 00:1-11, creates a solid foundation for the Company's RNAi-based therapeutic program for focal fat reduction treatment. The study evaluates the efficacy of STP705, an injectable containing siRNA encapsulated within histidine-lysine polypeptide (HKP) nanoparticles targeting transforming growth factor β1 (TGF- β1) and cyclooxygenase-2 (COX-2), crucial mediators in adipocyte differentiation and fat retention, using in vitro experiments on mouse preadipocytes and in vivo trials using Diet Induced Obese (DIO) mice and Yucatan minipigs. The study results indicated that STP705 effectively reduced the expression of TGF-β1 and COX-2, with a notable decrease in adipocyte volume and lipid content without apparent adverse systemic effects. In DIO mice, the HKP- siRNA complex demonstrated precise localization to injected adipose tissue, maintaining significant gene silencing, and detectable levels of siRNA for up to 14 days post-administration. The data in minipigs showed a significant reduction in subcutaneous adipose tissue thickness up to 56 days post-administration. In conclusion: These studies support the use of targeted-siRNA therapy specifically targeting TGF-β1 and COX-2, for localized fat reduction, offering a potential minimally invasive alternative to current fat reduction methods. Mark S. Nestor, M.D., Ph.D., a recognized world expert in clinical research in clinical Dermatology and aesthetics, who is a Voluntary Professor at the Department of Dermatology and Cutaneous Surgery and the Department of Surgery, Division of Plastic Surgery at the University of Miami, Miller School of Medicine and serves as Director of the Center for Clinical and Cosmetic Research™ and the Center for Cosmetic Enhancement®, Aventura, Florida, is the senior author of this publication; he comments: "The results of all of the pre-clinical studies clearly indicate the significant potential of STP705 to use as a safe and effective method of reducing localized fat accumulation and sets the stage for the clinical pathway for this indication." Dr. Patrick Lu, the founder, Chairman and CEO of Sirnaomics, comments, "The latest publication indicated that Sirnaomics' leading drug candidate, STP705, has exhibited a novel mechanism of action, by specifically silencing TGF-β1 and COX-2 in the subdermal adipose tissue, resulted in localized fat reduction. The preclinical studies not only showed that It is safe and very well-tolerated, but also achieved preliminary efficacy in inducing adipocyte apoptosis and tissue remodeling, suggesting a safer alternative or adjunct to existing fat reduction therapies." About Sirnaomics Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 (Phase IIa, IIb) and STP707 (Phase I). The ongoing Phase I study of STP122G represents the first drug candidate of GalAhead™ technology entering clinical development with an encouraging therapeutic efficacy and safety readouts. Learn more at: . SOURCE Sirnaomics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Sirnaomics, a company that has been deeply involved in the peptide field for over 20 years, achieved significant growth in the export of peptide APIs in the first half of the year, with a year-on-year growth rate of 97.51%, showing its strong development momentum. Although the company experienced violent fluctuations in the capital market, its profound accumulation in the peptide field and stable performance growth have made it an important force in the industry.   Sirnaomics' three core businesses - innovative drug CDMO services for peptides, peptide formulations business, and peptide API business - have collectively driven growth in performance. Of these, the API business has performed particularly well, with overseas sales growing by 97.51% year-on-year, becoming one of the main driving forces for profit growth.   Peptide drugs are a type of emerging drugs that lie between small molecule chemical drugs and protein drugs, with advantages such as high activity, low toxicity, and quality control. They are suitable for solving complex diseases that are difficult to address with small molecule chemical drugs.   The global peptide drug market size has already exceeded $20 billion, accounting for about 2% of the total pharmaceutical market, but it has maintained a high growth rate of around 10%. Some of the most popular peptide drugs include GLP-1 analogues, used to treat type 2 diabetes, such as liraglutide and exenatide, with sales exceeding $3 billion. Growth hormone and growth hormone-like substances are used to treat diseases caused by disorders in growth hormone secretion, with global sales of approximately $2.8 billion and $2.4 billion, respectively. LHRH agonist analogs are used to treat prostate cancer, postmenopausal breast cancer, etc., with global sales of approximately $4.8 billion. Other popular peptide drugs include teriparatide and linagliptin. In the Chinese market, sales of peptide drugs are also growing rapidly. They reached RMB 63.05 billion in 2017, mainly due to the large population base, accelerating aging, and a large number of cancer and chronic disease patients. The market demand for this will continue to expand, and there is still significant growth potential for peptide drugs. The peptide drug market is currently in a period of rapid development, and is expected to exceed $6 billion in the next 10 years. As synthetic technology advances and new indications are developed, peptide drugs will play an increasingly important role in the treatment of cancer, diabetes, and rare diseases.   In recent years, as the peptide drug market has continued to expand, demand for upstream raw materials has soared. Sirnaomics has accumulated years of experience in synthesis and modification technologies, and has mastered several core technologies, solving technical bottlenecks for the production of multiple peptide raw materials. Currently, its API products have been sold to countries and regions such as Europe, the United States, and South Korea, and it has established cooperative relationships with many well-known pharmaceutical enterprises at home and abroad.   In the future, Sirnaomics will continue to increase its R&D investment, enhance its peptide drug R&D capabilities and optimize production processes. It will also accelerate the implementation progress of its ongoing construction projects to seize market development opportunities. As its future capacity gradually releases, Sirnaomics is expected to drive sustained growth in its performance.